NCT05190471View on ClinicalTrials.gov

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2027

Conditions
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Interventions
DRUG

BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide

Dose escalation of BP1002 monotherapy

DRUG

Decitabine (in combination with BP1002)

Dose expansion of BP1002 in combination with decitabine

Trial Locations (4)

10021

RECRUITING

Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York

77030

RECRUITING

MD Anderson Cancer Center, Houston

90024

RECRUITING

UCLA Medical Center, Los Angeles

92037

RECRUITING

Scripps Green Hospital, La Jolla

Sponsors
All Listed Sponsors
lead

Bio-Path Holdings, Inc.

INDUSTRY